Regional anesthesia to reduce inflammation during vaso‑occlusive crises in sickle cell disease
Official title: Impact of Regional Anesthesia on Inflammatory Mechanisms During Vaso-occlusive Crisis in Sickle Cell Patients
Run by Centre Hospitalier Universitaire de la Guadeloupe · NCT07001189 · Data updated 2026-11-12
This project will test whether giving regional (loco‑regional) anesthesia to adults hospitalized for sickle cell vaso‑occlusive crises reduces inflammatory markers and speeds recovery compared with usual care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 34 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de la Guadeloupe Academic / other |
| Locations | 1 site (Pointe-à-Pitre) |
| Status | Recruiting |
| Started | February 5, 2025 |
| Main results expected | February 5, 2027 |
| Study ends | February 5, 2027 |
| Registry record updated | June 3, 2025 |
| Trial ID | NCT07001189 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (over 18) with a vaso‑occlusive crisis who are hospitalized at the CHU de la Guadeloupe and meet local eligibility (not pregnant, no blood transfusion in past 3 months, and covered by French social security) are the intended participants.
✕Probably not a fit
Patients who are pregnant, recently transfused, lack French social security coverage, or who do not receive regional anesthesia during their hospitalization would not be included and therefore would not directly benefit from this study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational comparison of patients hospitalized for vaso‑occlusive crises who receive loco‑regional (regional) anesthesia versus those who do not. Blood samples will be analyzed for inflammatory markers such as microparticles, cytokines, and neutrophil extracellular traps at defined timepoints during crisis and resolution. The protocol aims to describe whether regional anesthesia is associated with a blunted inflammatory response and faster clinical improvement. The work is conducted at the Centre Hospitalier Universitaire de la Guadeloupe and uses routine clinical care decisions rather than randomized interventions.
Why it matters
Potential benefit: If successful, findings could support using regional anesthesia to reduce inflammation and pain duration during crises, possibly shortening hospital stays and lowering complications.
How similar studies have gone: Preclinical and in vitro studies show local anesthetics have anti‑inflammatory effects, but no clinical study has yet demonstrated cellular anti‑inflammatory effects of regional anesthesia specifically in sickle cell patients, so the approach is promising but clinically unproven in this population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients adult \>18 years * patients with vaso-occlusive crisis Exclusion Criteria: * Pregnant or breastfeeding women * Blood transfusion within the last 3 months * Lack of affiliation with the French social security system * Protected individuals
Where it's running
-
Chu de La Guadeloupe
Pointe-à-Pitre, Guadeloupe Recruiting
Study contacts
- Principal investigator: Amelie Rolle, MD — CHU de la Guadeloupe
- Study coordinator: Valérie Hamony Soter
- Email: valerie.soter@chu-guadeloupe.fr
- Phone: +590590934677
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-dose ketamine for sickle cell vaso-occlusive pain in children and young adults
This trial will test whether adding a low (sub-dissociative) dose ketamine infusion to usual IV opioid pain medicine helps children and young adults (ages 5–20) with sickle cell disease have better pain relief and remain safe during a vaso-occlusive episode.
-
Morphine removal and kidney filtering in adults with sickle cell crises in intensive care
This project will test how quickly morphine is cleared from the body in adults with sickle cell disease admitted to intensive care for vaso-occlusive crisis or acute chest syndrome, and whether faster kidney filtering leads to lower morphine levels.
-
Cerebrovascular Reactivity Testing with HD-DOT in Sickle Cell Patients
This study tests whether high-density diffuse optical tomography can measure brain blood flow and oxygen use in people with sickle cell disease, to see how these signals relate to stroke risk.
-
Adapting and testing PEN-Plus in Zambian primary care
Aiming to see if the PEN-Plus package can be adapted and used in two Zambian hospitals to better manage chronic diseases like heart disease, diabetes, hypertension, and sickle cell in primary care.
-
Newborn Sickle Cell Screening in Mozambique
We’re testing a three-part plan to help babies in Mozambique get diagnosed early for sickle cell disease and start care quickly.
-
Optimizing Hydroxyurea in Children with Sickle Cell in Africa
This study tests whether raising hydroxyurea to a maximum tolerated dose is safe and beneficial for Ugandan children with sickle cell anemia already taking a fixed daily dose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.